Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein
KEYWORDS: people, vte, prophylaxis, risk, vte prophylaxis, surgery, lmwh, use, risk vte, pharmacological, consider, bleeding, undergoing, people undergoing, person

See NICE's information on prescribing medicines. 1.5.1 If using pharmacological VTE prophylaxis for people with renal impairment, choose either LMWH or unfractionated heparin (UFH). [2018] 1.5.2 If needed, reduce the dose of LMWH and UFH for people with renal impairment. Base the decision on multidisciplinary or senior opinion, or locally agreed protocols. [2018] 1.6 Interventions for people with cancer In March 2018: • the use of LMWH in young people under 18 in recommendations 1.6.2 and 1.6.3 was off label • the use of aspirin in recommendation 1.6.2 was off label. See NICE's information on prescribing medicines. 1.6.1 Do not offer VTE prophylaxis to people with cancer who are receiving cancer- modifying treatments such as radiotherapy, chemotherapy or immunotherapy and who are mobile, except as outlined in recommendations 1.6.2 and 1.6.3, unless they are also at increased risk of VTE because of something other than the cancer. [2018] 1.6.2 Consider pharmacological VTE prophylaxis for people with myeloma who are receiving chemotherapy with thalidomide, pomalidomide or lenalidomide with steroids. Choose either: • aspirin (75 mg or 150 mg) or • LMWH. [2018] 1.6.3 Consider pharmacological VTE prophylaxis with LMWH for people with pancreatic cancer who are receiving chemotherapy. [2018] 1.6.4 If
